Veradermics, Incorporated MANE
124.39 USD -0.47 (-0.38%)
Regular-session close
123.01 -1.38 -1.11%
Pre-market · Nov 20, 8:14 AM ET
121.91 Day range 128.69
32.00 52-week range 156.63
- YTD
- +229.51%
- 1 year
- +229.51%
News
fool.com Which Healthcare ETF Is Best for the Long Term: State Street’s XPH or Invesco’s PBE? Lower fees and a steadier beta set one healthcare ETF apart, while the rival fund's richer dividend could sway income-focused investors.benzinga.com Citigroup Maintains Buy on Veradermics, Raises Price Target to $175 Citigroup analyst Geoff Meacham maintains Veradermics (NYSE:MANE) with a Buy and raises the price target from $160 to $175.
benzinga.com Leerink Partners Maintains Outperform on Veradermics, Raises Price Target to $150 Leerink Partners analyst Marc Goodman maintains Veradermics (NYSE:MANE) with a Outperform and raises the price target from $135 to $150.
benzinga.com Veradermics Eyes Historic FDA First After Strong Hair Loss Pill Trial Results Veradermics reports positive Phase 2/3 trial data for its oral hair loss pill, paving the way for potential FDA approval. MANE shares rise.benzinga.com Veradermics Announces Topline Results From Registration-Directed Phase 2/3 Trial Of VDPHL01, Demonstrating Efficacy In Male Pattern Hair Loss VDPHL01, a novel orally-administered extended-release minoxidil formulation, demonstrated Target Area Hair Count (TAHC) deepening in twice-daily (BID) and maintenance in once-daily (QD) treatment…
benzinga.com B. Riley Securities Maintains Buy on Veradermics, Raises Price Target to $204 B. Riley Securities analyst Mayank Mamtani maintains Veradermics (NYSE:MANE) with a Buy and raises the price target from $170 to $204.
